River Blindness or onchocerciasis is caused by the prelarval (microfilaria) and adult stages of the filarial nematode Onchocerca volvulus. The disease is transmitted by the bite of certain species of female Simulium flies (black flies) that bite by day and are found near rapidly flowing rivers and streams. Onchocerciasis is endemic in more than 25 nations located in a broad band across the central part of Africa. Small endemic foci are also present in the Arabian Peninsula (Yemen) and in the Americas (Brazil, Colombia, Ecuador, Guatemala, southern Mexico, and Venezuela)
In a small, randomized Phase I/II clinical trial (SAT1), researchers at University of California San Diego School of Medicine say a 100-year-old drug called suramin, originally developed to treat African sleeping sickness, was safely administered to children with autism spectrum disorder (ASD), who subsequently displayed measurable, but transient, improvement in core symptoms of autism.
Since 2007, the World Health Organization (WHO) has been reporting outstanding success in dealing with neglected tropical diseases (NTDs) with 1 billion people estimated to have received treatments in 2015.
Research teams from the National Institutes of Health and abroad have identified the first inhibitor of an enzyme long thought to be a potential drug target for fighting disease-causing parasites and bacteria.
SUGAR-based adjuvants from Australia are boosting the effectiveness of vaccines to target some of the world’s deadliest diseases.
The parasite that causes river blindness infects about 37 million people in parts of Africa and Latin America, causing blindness and other major eye and skin diseases in about 5 million of them.
Scientists have sequenced the genome of the parasitic worm responsible for causing onchocerciasis--an eye and skin infection more commonly known as river blindness.
Geographers at the University of Southampton have completed a large scale data and mapping project to track the flow of internal human migration in low and middle income countries.
PATH and Standard Diagnostics/Alere announced today the commercial availability of two rapid diagnostic tools for onchocerciasis and lymphatic filariasis. Designed for use in disease surveillance, the antibody-based tests are part of a suite of diagnostic innovations intended to support the elimination of neglected tropical diseases (NTDs), a group of illnesses that affect more than a billion people worldwide.
The acclaimed public television documentary series Global Health Frontiers expands to a weekly newsmagazine with four one-hour episodes combining compelling journalism from the leading edges of global health developments with a fast-paced and energetic style.
Many of the drugs we use in hospitals – antibiotics, antifungals and anti-cancer drugs, to name but a few – are produced by bacteria that live in the soil beneath our feet.
The world's first vaccine for a disease that causes misery for millions in Africa could be tested within five years.
Researchers at Washington University School of Medicine in St. Louis have received a $7 million grant from the Bill & Melinda Gates Foundation aimed at eliminating river blindness and elephantiasis, two neglected tropical diseases that annually sicken millions.
New Smartphone technology has been developed that can detect and count wriggling parasitic worms in a drop of blood...
Today the national science academies of the G7 countries handed three statements to their respective heads of government for discussion during the G7 summit at Schloss Elmau in early June 2015. The papers on antibiotic resistance, neglected and poverty-related diseases, and the future of the ocean were drawn up by the seven national academies under the aegis of the German National Academy of Sciences Leopoldina.
WHO urges affected countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low and middle income countries for the period 2015-2030.
The Drugs for Neglected Diseases initiative has been awarded US$ 10 million by the United States Agency for International Development to develop new treatments for onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) - the first-ever USAID grant for neglected tropical disease research and development (R&D).
Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.
Grand Challenges Canada, funded by the Government of Canada, today announced $1.2 million in funding for 11 new global health innovations implemented in member states of La Francophonie.
Almost $2 million is being invested by the Bill & Melinda Gates Foundation to help fight major parasitic diseases of the developing world.
A new test will accelerate global progress toward eliminating onchocerciasis, a leading cause of preventable blindness in Africa. PATH, an international nonprofit health organization, today announced the availability of the SD BIOLINE Onchocerciasis IgG4 rapid test, manufactured and distributed by Standard Diagnostics, Inc.